Skip to main content
. Author manuscript; available in PMC: 2023 Apr 29.
Published in final edited form as: J Neurosurg. 2021 Oct 29;136(6):1567–1575. doi: 10.3171/2021.6.JNS21925

Figure 2:

Figure 2:

Survival of patients with highly diffuse tumors by SMR threshold of 90% among patients with GBM with GTR of the contrast-enhancing portion. The mean survival for patients receiving < 90% SMR was 13.2 months compared with 22.1 months for those receiving > 90% SMR (p = 0.047).